Pimozide

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Retrieved on: 
Donnerstag, Juni 29, 2023
CLL, Hypersensitivity, Lymphocytosis, Pimozide, Arrhythmia, Tacrolimus, Chronic lymphocytic leukemia, SLL, Liver disease, Simvastatin, Magnesium, Atorvastatin, Antifungal, Person, QT, Sirolimus, QT interval, Ergot, Alkaline phosphatase, Plasma, Kidney, Lovastatin, Ergotism, Patient, Azole, Risk, Electrolyte, Ergotamine, Dihydroergotamine, Tumor lysis syndrome, Ciclosporin, ALT, Quinidine, Rhabdomyolysis, Potassium, AST, Venetoclax, Pharmaceutical industry, Posaconazole, CYP3A4

Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.

Key Points: 
  • Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.
  • Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
  • Reserve azole antifungals, including posaconazole injection, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
  • Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Retrieved on: 
Donnerstag, Juni 29, 2023
CLL, Hypersensitivity, Lymphocytosis, Pimozide, Arrhythmia, Tacrolimus, Chronic lymphocytic leukemia, SLL, Liver disease, Simvastatin, Magnesium, Atorvastatin, Antifungal, Person, QT, Sirolimus, QT interval, Ergot, Alkaline phosphatase, Plasma, Kidney, Lovastatin, Ergotism, Patient, Azole, Risk, Electrolyte, Ergotamine, Dihydroergotamine, Tumor lysis syndrome, Ciclosporin, ALT, Quinidine, Rhabdomyolysis, Potassium, AST, Venetoclax, Pharmaceutical industry, Posaconazole, CYP3A4

Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.

Key Points: 
  • Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.
  • Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
  • Reserve azole antifungals, including posaconazole injection, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
  • Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

Retrieved on: 
Dienstag, Juni 6, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, MSD, Cytomegalovirus, Neutropenia, Male, Pimozide, Aciclovir, IV, AE, Culture, Alkaloid, Simvastatin, Aes, Myopathy, Valganciclovir, MRK, HSCT, Immunotherapy, Merck & Co., Hypertension, Incidence, Ergotism, Diarrhea, Drug, Patient, Leukopenia, Blood, CMV, Kidney, Ciclosporin, ALT, Transplant, Rhabdomyolysis, AST, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thrombocytopenia, NYSE, Food, Safety, Disease, Medical device, Vaccine, Pharmaceutical industry, Merck

PREVYMIS is an antiviral agent that was initially approved by the FDA in 2017 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

Key Points: 
  • PREVYMIS is an antiviral agent that was initially approved by the FDA in 2017 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
  • Increased pimozide concentrations due to concomitant administration of PREVYMIS may lead to QT prolongation and torsades de pointes.
  • Study drug was initiated between Day 0 and Day 7 post-kidney transplant and continued through Week 28 (~200 days) post-transplant.
  • The most common primary reasons for transplant were congenital cystic kidney disease (17%), hypertension (16%), and diabetes/diabetic nephropathy (14%).

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

Retrieved on: 
Dienstag, März 22, 2022
General Health, Pharmaceutical, Health, Other Health, MSD, Hospital, Risk, Pimozide, Abstract, Alkaloid, Viremia, MD Anderson Cancer Center, Plasma, MRK, EBMT, Myopathy, Rhabdomyolysis, Record, Simvastatin, Observation, POR, PubMed, Ergotism, Cytomegalovirus, NYSE, Embase, Mortality, Adult, CMV, HSCT, Publication, Patient, Medicine, Food, Nausea, Drug, Center, IV, Infection, Ciclosporin, Drug interaction, Graft-versus-host disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Society for Primary Immunodeficiencies, Merck & Co., Blood, Tachycardia, Atrial fibrillation, Enzyme, CYP3A, Meta-analysis, University, Disease, Midazolam, Pharmaceutical industry, Airline, Fertilizer, Coffee, Merck, PREVYMIS (LETERMOVIR), CMV AND TREATMENT, MERCK

Consistent results were observed at 200 days of follow-up with respect to CMV reactivation, clinically significant CMV infection, and CMV disease.

Key Points: 
  • Consistent results were observed at 200 days of follow-up with respect to CMV reactivation, clinically significant CMV infection, and CMV disease.
  • CMV infection is a common clinically significant complication in these patients and early CMV reactivation after alloHCT is associated with increased mortality.
  • We are encouraged that the findings from this comprehensive literature review and meta-analysis of real-world observational studies reinforce the effectiveness of PREVYMIS in these patients at risk for CMV infection and disease.
  • The objective of the analysis was to assess the effectiveness of primary prophylaxis with PREVYMIS among adults undergoing alloHCT using systematic literature review and meta-analysis of data from real-world observational studies.